Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Type
Public
HQ
Petaluma, US
Size (employees)
38 (est)+12%
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is headquartered in Petaluma, US

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Office Locations

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) has offices in Petaluma and Herten
Petaluma, US (HQ)
1129 N McDowell Blvd
Herten, NL
6049 LX Herten/Roermond

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financials and Metrics

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financials

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s revenue was reported to be $12.8 m in FY, 2017
USD

Revenue (Q1, 2018)

3.8 m

Gross profit (Q1, 2018)

1.8 m

Gross profit margin (Q1, 2018), %

46%

Net income (Q1, 2018)

(3.5 m)

EBIT (Q1, 2018)

(3.4 m)

Market capitalization (05-Dec-2016)

20.9 m

Closing share price (05-Dec-2016)

4.9

Cash (30-Jun-2017)

12.6 m

EV

8.3 m
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s current market capitalization is $20.9 m.
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

13.7 m13.9 m15.1 m12.8 m

Revenue growth, %

1%9%(15%)

Cost of goods sold

5.3 m6.6 m7.9 m7.2 m

Gross profit

8.4 m7.3 m7.2 m5.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

4.1 m3.3 m3.4 m3.3 m3.2 m3.7 m4.1 m3.8 m3.8 m4.1 m3.4 m3.8 m

Cost of goods sold

1.4 m1.2 m1.5 m1.5 m1.6 m1.8 m2 m2.3 m1.9 m2 m1.7 m2.1 m

Gross profit

2.7 m2.1 m1.9 m1.7 m1.7 m1.9 m2.1 m1.5 m1.9 m2.1 m1.7 m1.8 m

Gross profit Margin, %

66%64%56%53%51%51%52%40%50%51%51%46%
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.5 m6.1 m7.5 m17.5 m

Accounts Receivable

1.8 m1.5 m2.3 m2.1 m

Inventories

647 k592 k1.5 m2.2 m

Current Assets

9.5 m9.6 m12.9 m22.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

3.2 m3.4 m5 m3.5 m2.2 m8.8 m8 m6.1 m5 m3.3 m19 m12.6 m

Accounts Receivable

2.4 m2.6 m2 m2.1 m1.4 m2.5 m2.6 m2.7 m2.6 m2.3 m2 m2.7 m

Inventories

749 k970 k1.3 m1.2 m1.4 m1.5 m1.7 m1.6 m2 m2.1 m2.1 m2.4 m

Current Assets

6.9 m7.5 m8.7 m7.3 m5.2 m13.3 m12.7 m11.1 m10.5 m8.4 m25.1 m19.3 m
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.7 m(8.2 m)(10.2 m)9.3 m

Depreciation and Amortization

284 k253 k244 k248 k

Accounts Receivable

(88 k)40 k(1.3 m)34 k

Inventories

(126 k)(627 k)(382 k)(675 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(1.4 m)(611 k)(70 k)(718 k)(5.9 m)(2.3 m)(1.8 m)(3.1 m)(2.6 m)(1.9 m)16.2 m

Accounts Receivable

2 m2.1 m1.4 m2.5 m2.6 m2.7 m2.6 m2.3 m2 m

Accounts Payable

943 k1.1 m942 k1.2 m1.2 m1.5 m1.4 m1.3 m1.1 m
Y, 2017

EV/EBIT

-2.5 x

Financial Leverage

1.2 x
Show all financial metrics

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Market Value History

Market Position of Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s Web-traffic and Trends

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Company Life and Culture

You may also be interested in